Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by StevenBirchon May 06, 2022 11:44am
182 Views
Post# 34662333

RE:2022 for M&A

RE:2022 for M&A This is our year, everything is coming together. Would be nice if they have an in-person AGM with Vera and data replacing Kipton, Shawn and the dreaded PP of 2019. 

Maybe Roger could open with "miss me yet?" and announce his return to CEO for early in '23.


LaserStock29 wrote: Bolt on deals


2022 could be a “pretty buoyant year” for biopharma M&A, and not just because large companies have accumulated plenty of cash.

The need remains clear for pharmas to scale up and diversify in different therapeutic areas, said Glenn Hunzinger, U.S. pharmaceutical and life sciences consulting solutions leader at PwC, in an interview.


The entire life sciences sector could pull off $350 billion to $400 billion worth of M&A deals in 2022, PwC projects. Besides a flurry of $5 billion to $15 billion biotech takeovers, the accounting firm also sees opportunities for large buyouts of around $50 billion or even a “transact-to-transform” megadeal at $100 billion or more.

In a report in December, RBC Capital Markets analysts also projected that “a rebound in M&A is imminent,” given that large companies now have stronger balance sheets while still have looming patent cliffs to fight.

Valuations of small- and mid-cap biotechs have been under pressure recently, making them more affordable and attractive buyout targets, the team said.
As for the size of potential deals, the RBC analysts said they expect single-asset companies in mid- to late-stage clinical development valued at around $1 billion to $5 billion will be the “sweet spot” for most M&A in 2022, but added that “we may be due for a larger blockbuster deal.”

Mizuho analyst Salim Syed also thinks companies could be buyers, especially when they’re under growth pressure. But he argued that without a clear shift in overall dealmaking sentiment, 2022 is going to be more or less the same as 2021 for biopharma M&A.

--------------------------------------------
No Excuses......   


<< Previous
Bullboard Posts
Next >>